bioRxivBioinformaticsPreprint
PKMYT1 is a computationally predicted target for kidney cancer
Abstract
Protein Kinase Membrane Associated Tyrosine/Threonine 1 (PKMYT1) is an understudied member of the serine/threonine protein kinase family. PKMYT1 is listed as a dark kinase according to the Illuminating the Druggable Genome (IDG) target development level classification. Using a combination of bioinformatics tools that we developed, we predict that targeting PKMYT1 is potentially beneficial for treating kidney cancer.
- Citations
- 1
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- The Clinical Kinase Index: Prioritizing Understudied Kinases as Targets for the Treatment of Cancer
Derek J. Essegian, Rimpi Khurana, … Stephan C. Schürer·Cell Reports MedicinePeer-reviewed·Oct 1, 2020
- An integrative proteomics approach identifies tyrosine kinase KIT as a novel therapeutic target for SPINK1-positive prostate cancer.
N. Manzar, U. K. Khan, … B. Ateeq·bioRxiv·Jul 24, 2023
- Discoidan Domain Receptor 1 (DDR1) Tyrosine Kinase is Upregulated in PKD Kidneys But Does Not Play a Role in the Pathogenesis of Polycystic Kidney Disease
E. Y. Skolnik, I. Soomro, … ALL ON MAIN LIST·bioRxiv·Jan 22, 2019
- Cellular And Molecular Effects Of Understudied Kinase Pregnancy Upregulated Non-Ubiquitous Calcium-Calmodulin Dependent Kinase (PNCK) In Renal Cell Carcinoma.
Derek J. Essegian, Valery A. Chavez-Perez, … Jaime Rafael Merchan·bioRxiv·May 9, 2022
- Pyruvate kinase M1 suppresses development and progression of prostate adenocarcinoma
S. M. Davidson, J. E. Heyman, … M. G. Vander Heiden·bioRxiv·May 9, 2021
- Tyrosine phosphoproteome profiling identifies cell-intrinsic signals limiting the efficacy of tyrosine kinase inhibitor therapies
Cameron T. Flower, Forest M. White·Proceedings of the National Academy of SciencesPeer-reviewed·Mar 25, 2026